Beam Therapeutics (BEAM) Operating Income (2019 - 2026)
Beam Therapeutics (BEAM) reported Operating Income of -$107.2 million for Q1 2026, up 10.12% year-over-year from -$97.4 million in Q1 2025, and down 514.59% on a QoQ basis from -$17.4 million in Q4 2025.
Beam Therapeutics (BEAM) has 8 years of Operating Income data on file, last reported at -$107.2 million in Q1 2026.
- Quarterly Operating Income rose 10.12% year-over-year to -$107.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$371.6 million (up 13.72% YoY) and the FY2025 annual result came in at -$383.7 million, up 7.67% from the prior year.
- Operating Income retreated to -$107.2 million in Q1 2026 per BEAM's latest filing, from -$17.4 million in the prior quarter.
- Across five years, Operating Income topped out at $132.9 million in Q4 2023 and bottomed at -$126.8 million in Q3 2025.
- The 5-year median for Operating Income is -$102.1 million (2023), against an average of -$83.6 million.
- The widest annual swing landed in 2023, when Operating Income surged 249.3%; it then sank 175.3% in 2024.
- Tracing BEAM's Operating Income over 5 years: stood at -$89.0 million in 2022, then surged by 249.3% to $132.9 million in 2023, then slumped by 175.3% to -$100.0 million in 2024, then soared by 82.56% to -$17.4 million in 2025, then tumbled by 514.59% to -$107.2 million in 2026.
- Per Business Quant, the three latest BEAM Operating Income figures stand at -$107.2 million (Q1 2026), -$17.4 million (Q4 2025), and -$126.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - | -107.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107.22 Mn |
| Dec 31, 2025 | -17.45 Mn |
| Sep 30, 2025 | -126.81 Mn |
| Jun 30, 2025 | -120.15 Mn |
| Mar 31, 2025 | -119.29 Mn |
| Dec 31, 2024 | -100.04 Mn |
| Sep 30, 2024 | -106.50 Mn |
| Jun 30, 2024 | -104.90 Mn |
| Mar 31, 2024 | -104.13 Mn |
| Dec 31, 2023 | 132.86 Mn |
| Sep 30, 2023 | -108.27 Mn |
| Jun 30, 2023 | -102.15 Mn |
| Mar 31, 2023 | -98.93 Mn |
| Dec 31, 2022 | -88.99 Mn |
| Sep 30, 2022 | -91.30 Mn |
| Jun 30, 2022 | -81.97 Mn |
| Mar 31, 2022 | -76.23 Mn |
| Dec 31, 2021 | -63.48 Mn |
| Sep 30, 2021 | -69.63 Mn |
| Jun 30, 2021 | -58.97 Mn |
| Mar 31, 2021 | -200.37 Mn |
| Dec 31, 2020 | -40.80 Mn |
| Sep 30, 2020 | -37.32 Mn |
| Jun 30, 2020 | -26.29 Mn |
| Mar 31, 2020 | -28.36 Mn |
| Dec 31, 2019 | -26.37 Mn |
| Sep 30, 2019 | -18.02 Mn |
| Jun 30, 2019 | -17.65 Mn |
| Mar 31, 2019 | -13.11 Mn |